OCYTOCIN: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
OCYTOCIN
Largest movements
- Cash +€47,044
up €47,044 (+456.1%), from €10,314 to €57,358
mainly Other debts (+€42,675) and Receivables within one year (+€21,720)
- Receivables within one year -€21,720
down €21,720 (-26.8%), from €80,951 to €59,231
of which Other amounts receivable: -€15,924
- Other debts +€42,675
up €42,675 (+52.9%), from €80,692 to €123,367
- Profit (loss) carried forward -€23,047
down €23,047 (-14.6%), from €157,336 to €134,289
- Tax, wage and social debts +€6,000
new in 2025: €6,000
- Other operating charges -€17,862
down €17,862 (-87.6%), from €20,379 to €2,518
- Gross operating margin +€2,616
up €2,616 (+12.5%), from €20,888 to €23,504
- Depreciation -€839
down €839 (-17.7%), from €4,728 to €3,889
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €250,792 | €274,269 | +€23,477 | +9.4% |
| Fixed assets | 21/28 | €157,782 | €156,198 | -€1,584 | -1.0% |
| Tangible fixed assets | 22/27 | €157,782 | €156,198 | -€1,584 | -1.0% |
| Furniture and vehicles | 24 | €157,782 | €156,198 | -€1,584 | -1.0% |
| Current assets | 29/58 | €93,010 | €118,071 | +€25,061 | +26.9% |
| Amounts receivable within one year | 40/41 | €80,951 | €59,231 | -€21,720 | -26.8% |
| Trade receivables | 40 | €48,581 | €42,785 | -€5,796 | -11.9% |
| Other amounts receivable | 41 | €32,370 | €16,446 | -€15,924 | -49.2% |
| Cash at bank and in hand | 54/58 | €10,314 | €57,358 | +€47,044 | +456.1% |
| Deferred charges and accrued income | 490/1 | €1,745 | €1,483 | -€263 | -15.1% |
| Total equity and liabilities | 10/49 | €250,792 | €274,269 | +€23,477 | +9.4% |
| Equity | 10/15 | €162,336 | €139,289 | -€23,047 | -14.2% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €157,336 | €134,289 | -€23,047 | -14.6% |
| Amounts payable | 17/49 | €88,456 | €134,980 | +€46,524 | +52.6% |
| Amounts payable within one year | 42/48 | €88,456 | €134,980 | +€46,524 | +52.6% |
| Financial debts | 43 | €762 | €0 | -€762 | -100.0% |
| Credit institutions | 430/8 | €762 | €0 | -€762 | -100.0% |
| Trade debts | 44 | €7,002 | €5,613 | -€1,390 | -19.8% |
| Suppliers | 440/4 | €7,002 | €5,613 | -€1,390 | -19.8% |
| Taxes, remuneration and social security | 45 | - | €6,000 | +€6,000 | |
| Taxes | 450/3 | - | €6,000 | +€6,000 | |
| Other amounts payable | 47/48 | €80,692 | €123,367 | +€42,675 | +52.9% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €4,728 | €3,889 | -€839 | -17.7% |
| Other operating charges | 640/8 | €20,379 | €2,518 | -€17,862 | -87.6% |
| Gross operating margin | 9900 | €20,888 | €23,504 | +€2,616 | +12.5% |
| Operating profit (loss) | 9901 | -€4,218 | €17,098 | +€21,316 | |
| Financial income | 75/76B | - | €3 | +€3 | |
| Recurring financial income | 75 | - | €3 | +€3 | |
| Financial charges | 65/66B | €152 | €147 | -€5 | -3.2% |
| Recurring financial charges | 65 | €152 | €147 | -€5 | -3.2% |
| Profit (loss) for the period before taxes | 9903 | -€4,371 | €16,953 | +€21,324 | |
| Profit (loss) for the period | 9904 | -€4,371 | €16,953 | +€21,324 | |
| Profit (loss) for the period to be appropriated | 9905 | -€4,371 | €16,953 | +€21,324 |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 4 October 2026 via checked.be.